Syros Pharmaceuticals, Inc.
SYRSDelisted Mar 10, 2025- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001556263
Syros Pharmaceuticals, Inc. was delisted on Mar 10, 2025; its insiders filed their last Form 4 on Dec 4, 2024; 44 institutions reported holding it in 13F filings for Q4 2024, worth $1.20M in total; no superinvestor held it.
Key figures
- Market cap
- –
- Not available
- Insider buys
- 0
- Open market, last 90 days
- Insider sells
- 0
- Open market, last 90 days
- 13F holders
- 44
- Q4 2024, −21 vs. previous quarter
- 13F value
- $1.20M
- Reported value at the end of Q4 2024
- Superinvestors holding
- 0
- At the end of Q4 2024
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2023
- $9.94M
- −33.2% year over year
- Net income, FY2023
- -$164.6M
- No comparable prior period
- Free cash flow, FY2023
- -$110.0M
- No comparable prior period
- Revenue, Q3 FY2024
- –
- No comparable prior period
Revenue flow, FY2023
Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.
Net loss for FY2023: $164.6M (1656.3% of revenue).
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 25.6K
- Shares sold short
- Change
- −230
- −0.9% vs. previous
- Days to cover
- 2.42
- At average daily volume
Superinvestors holding SYRS, Q4 2024
Go to the superinvestors tabNo superinvestor reported holding SYRS at the end of Q4 2024.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Syros Pharmaceuticals, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Dec 4, 2024 (view filing)5:00 PM ET | Dec 2 | 2 days | Simonian Nancy ADirector | SSale | −37.1K | $0.2702 | −$10.0K | −90.3%4.00K after | |
| Nov 27, 2024 (view filing)5:00 PM ET | Nov 25 | 2 days | Simonian Nancy ADirector | SSale | −134.7K | $0.2653 | −$35.7K | −76.6%41.1K after | |
| Nov 20, 2024 (view filing)5:00 PM ET | Nov 18 | 2 days | Stephens KristinChief Development Officer | SSale | −36.1K | $0.22 | −$7.95K | −100.0%0 after | |
| Nov 20, 2024 (view filing)5:00 PM ET | Nov 18 | 2 days | Roth DavidChief Medical Officer | SSale | −12.1K | $0.1969 | −$2.38K | −100.0%0 after | |
| Nov 20, 2024 (view filing)5:00 PM ET | Nov 19 | 1 day | Quirk Gerald EChief Legal & Compliance Offic | SSale | −46.7K | $0.2212 | −$10.3K | −100.0%0 after | |
| Nov 20, 2024 (view filing)5:00 PM ET | Nov 18 | 2 days | Chee ConleyPresident & CEO | SSale | −134.8K | $0.1998 | −$26.9K | −100.0%0 after | |
| Nov 20, 2024 (view filing)5:00 PM ET | Nov 18 | 2 days | Haas JasonChief Financial Officer | SSale | −137.8K | $0.2103 | −$29.0K | −100.0%0 after | |
| Sep 12, 2024 (view filing) | Sep 10-12 | 2 days | Haas JasonChief Financial Officer | PPurchase | +100.0K | $1.61 | +$161.5K | +407.3%124.6K after | 3 lots |
| Sep 12, 2024 (view filing) | Sep 10-11 | 2 days | Chee ConleyPresident & CEO | PPurchase | +100.0K | $1.61 | +$161.0K | +444.4%122.5K after | 2 lots |
| Jul 2, 2024 (view filing) | Jun 28 | 4 days | Young Richard ADirector | SSale | −34.8K | $5.12 | −$178.4K | −81.3%8.00K after | 10b5-1 |
Top 10 13F holders, Q4 2024
See all 44 holdersThe largest institutional positions in Syros Pharmaceuticals, Inc. at the end of Q4 2024; share changes are against Q3 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Bain Capital Life Sciences Investors, LLC | 2,750,151 | $632.0K | 0.07% | 00.0% | Unchanged |
| BlackRock, Inc. | 277,253 | $63.7K | 0.00% | +15,674+6.0% | Added |
| Vanguard Group Inc | 268,154 | $61.7K | 0.00% | −685,159−71.9% | Reduced |
| Omega Fund Management, LLC | 251,270 | $57.8K | 0.04% | 00.0% | Unchanged |
| Acadian Asset Management LLC | 249,426 | $55.0K | 0.00% | +196,560+371.8% | Added |
| Geode Capital Management, LLC | 196,252 | $45.1K | 0.00% | −8,443−4.1% | Reduced |
| Affinity Asset Advisors, LLC | 150,000 | $34.5K | 0.01% | +150,000 | New |
| Citigroup Inc | 139,224 | $32.0K | 0.00% | +138,537+20,165.5% | Added |
| Qube Research & Technologies Ltd | 122,174 | $28.1K | 0.00% | +44,458+57.2% | Added |
| Two Sigma Securities, LLC | 107,742 | $24.8K | 0.00% | +107,742 | New |
Holders of 5% or more of SYRS
See all 1 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Syros Pharmaceuticals, Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Avidity Partners Management LP | 13G/A | 7.60%2.05M shares | – | Sep 20, 20225 filings | Feb 14, 2025 | SEC |